A5069074906- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Advanced biosensing and bioanalysis techniques
- Chemical Synthesis and Analysis
- Cancer Immunotherapy and Biomarkers
- Photochromic and Fluorescence Chemistry
- Click Chemistry and Applications
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Adenosine and Purinergic Signaling
- RNA Interference and Gene Delivery
- Glycosylation and Glycoproteins Research
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
University of Cambridge
2020-2024
Charles River Laboratories (United Kingdom)
2024
Cancer Research UK
2022
Peroxide-cleavable arylboronates are stable linkers for the generation of efficacious antibody–drug conjugates.
A 3-<italic>O</italic>-sulfo-β-galactose linker is cleaved by two lysosomal enzymes to release payloads from ADCs at targeted cancer cells.
Development and proof-of-concept for a photoswitchable peptide staple with the ability to trigger major change in binding affinity upon visible light irradiation.
A modular and metal-free chemical methodology for the synthesis of dual-functionalised antibody-drug conjugates.
We describe a versatile and tuneable thiol responsive linker system using thiovinylketones, which relies on the conjugate addition-elimination mechanism of Michael acceptors for traceless release therapeutics. In proof-of-principle study, we translate our findings to exhibit potent thiol-cleavable antibiotic prodrugs antibody-drug conjugates.
Abstract Leucine-rich repeat-containing G-protein receptor 5 (LGR5) has been characterised as a stem cell and cancer marker. Previous analyses of LGR5 transcript levels indicate high level expression discriminates malignancies such colorectal (CRC) pre-B acute lymphoblastic leukaemia (pre-B ALL) from healthy tissues suggesting protein may provide molecular handle for prognosis treatment. We have developed highly specific, affinity antibodies to the extracellular domain human (α-LGR5) that...